Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

The HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) is approved for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and taxane therapy, and has also demonstrated efficacy in the adjuvant setting in incomplete responders to neoadjuvant therapy. Des...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Hunter, Francis W., Barker, Hilary R., Lipert, Barbara, Rothé, Françoise, Gebhart, Géraldine, Piccart-Gebhart, Martine J., Sotiriou, Christos, Jamieson, Stephen M. F.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2019
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7054312/
https://ncbi.nlm.nih.gov/pubmed/31839676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0635-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados